Singapore – April 5, 2024 – Us2.ai, a leading MedTech firm backed by prominent investors including IHH Healthcare, Heal Partners, Peak XV Partners (formerly Sequoia India) and EDBI, announces FDA...
Study Finds the Corus® CAD Gene Expression Blood Test Influenced Primary Care Decision- Making in the Assessment of Patients with Suspected Obstructive Coronary Artery Disease
News | 03. 10. 2014
CardioDx
- IMPACT-PCP Study Results Reinforce the Clinical Utility of Corus CAD in the Primary Care Setting, Where Almost 8,000 Patients Present With Non-Acute Chest Pain and Related Symptoms Every Day -
- Clinicians Modified Their Diagnostic Strategy in 58% of Patients Following a Corus CAD Test Score -
PALO ALTO, Calif. – March 10, 2014 – CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the IMPACT-PCP (Investigation of a Molecular Personalized Coronary Gene Expression Test on Primary Care Practice Pattern) trial reinforcing the value of Corus® CAD as an initial diagnostic test for the evaluation of patients presenting with non-acute symptoms suggestive of obstructive coronary artery disease (CAD) in the primary care setting. The study appears in the March 2014 issue of the Journal of the American Board of Family Medicine.
